HUT70330A - Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer - Google Patents

Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer

Info

Publication number
HUT70330A
HUT70330A HU9401382A HU9401382A HUT70330A HU T70330 A HUT70330 A HU T70330A HU 9401382 A HU9401382 A HU 9401382A HU 9401382 A HU9401382 A HU 9401382A HU T70330 A HUT70330 A HU T70330A
Authority
HU
Hungary
Prior art keywords
stabilizer
preparation
composition
surfactant
factor viii
Prior art date
Application number
HU9401382A
Other languages
English (en)
Other versions
HU220194B (hu
HU9401382D0 (en
Inventor
Thomas Oesterberg
Angelica Fatouros
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9202878A external-priority patent/SE9202878D0/xx
Priority claimed from SE9301580A external-priority patent/SE9301580D0/xx
Priority claimed from SE9302006A external-priority patent/SE9302006D0/xx
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of HU9401382D0 publication Critical patent/HU9401382D0/hu
Publication of HUT70330A publication Critical patent/HUT70330A/hu
Publication of HU220194B publication Critical patent/HU220194B/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HU9401382A 1992-10-02 1993-10-01 Koagulációs faktor VIII-at tartalmazó készítmény és eljárás előállítására HU220194B (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9202878A SE9202878D0 (sv) 1992-10-02 1992-10-02 Protein formulation
SE9301580A SE9301580D0 (sv) 1993-05-07 1993-05-07 Protein formulation
SE9302006A SE9302006D0 (sv) 1992-10-02 1993-06-11 Protein formulation
PCT/SE1993/000793 WO1994007510A1 (en) 1992-10-02 1993-10-01 Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer

Publications (3)

Publication Number Publication Date
HU9401382D0 HU9401382D0 (en) 1994-08-29
HUT70330A true HUT70330A (en) 1995-09-28
HU220194B HU220194B (hu) 2001-11-28

Family

ID=27355693

Family Applications (2)

Application Number Title Priority Date Filing Date
HU9401382A HU220194B (hu) 1992-10-02 1993-10-01 Koagulációs faktor VIII-at tartalmazó készítmény és eljárás előállítására
HU95P/P00473P HU211670A9 (en) 1992-10-02 1995-06-28 Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU95P/P00473P HU211670A9 (en) 1992-10-02 1995-06-28 Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer

Country Status (19)

Country Link
US (2) US5733873A (hu)
EP (3) EP0627924B1 (hu)
JP (1) JP3905921B2 (hu)
KR (1) KR100303872B1 (hu)
AT (2) ATE198277T1 (hu)
CA (1) CA2124690C (hu)
CZ (1) CZ290342B6 (hu)
DE (2) DE69333974T2 (hu)
DK (1) DK0627924T3 (hu)
ES (1) ES2154650T3 (hu)
FI (1) FI111443B (hu)
GR (1) GR3035472T3 (hu)
HU (2) HU220194B (hu)
MX (1) MX9306133A (hu)
NO (1) NO942033L (hu)
NZ (1) NZ256921A (hu)
PT (1) PT627924E (hu)
SK (1) SK282483B6 (hu)
WO (1) WO1994007510A1 (hu)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
SE504074C2 (sv) † 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US6242417B1 (en) * 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US5514781A (en) * 1994-04-11 1996-05-07 Bayer Corporation Use of azoles as virucidal agents in solutions of biologically active proteins
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
US7244824B2 (en) 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
DK2130554T3 (da) 1999-02-22 2012-12-03 Univ Connecticut Albuminfrie faktor VIII-præparater
US20060099685A1 (en) * 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
NZ516400A (en) 1999-07-13 2004-02-27 Biovitrum Ab Stable factor VIII compositions
US6413537B1 (en) 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US8541002B2 (en) 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
SI1750733T1 (sl) * 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
EP1824988B1 (en) 2004-11-12 2017-04-19 Bayer HealthCare LLC Site-directed modification of fviii
US7884075B2 (en) 2004-12-27 2011-02-08 Baxter International Inc. Polymer-factor VIII-von Willebrand factor-conjugates
CA2606343A1 (en) 2005-04-28 2006-11-02 Novo Nordisk Health Care Ag A closed container comprising an activated factor vii polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit
CA2621273C (en) 2005-09-12 2014-07-29 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7982010B2 (en) * 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7683158B2 (en) * 2006-03-31 2010-03-23 Baxter International Inc. Pegylated factor VIII
CN105838699A (zh) 2006-12-15 2016-08-10 巴克斯艾尔塔公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
US8187799B2 (en) 2007-04-26 2012-05-29 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
KR101659458B1 (ko) 2007-12-27 2016-09-23 박스알타 인코퍼레이티드 세포 배양 방법
EP2113564A1 (en) * 2008-05-01 2009-11-04 Arecor Limited Protein formulation
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
WO2010026186A1 (en) * 2008-09-03 2010-03-11 Octapharma Ag New protecting compositions for recombinantly produced factor viii
EP2349341B1 (en) * 2008-10-15 2013-10-09 Baxter Healthcare SA Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
EP2385825B1 (en) * 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
HUE037595T2 (hu) 2008-12-31 2018-09-28 Revance Therapeutics Inc Injektálható botulinum toxin készítmények
EP2393828B1 (en) 2009-02-03 2016-10-12 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
ES2966234T3 (es) 2009-06-09 2024-04-18 Prolong Pharmaceuticals Llc Composiciones de hemoglobina
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
CA2766521C (en) 2009-06-25 2020-07-21 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
KR102068133B1 (ko) * 2009-07-27 2020-01-20 박스알타 인코퍼레이티드 혈액 응고 단백질 복합체
CN106110311A (zh) 2009-07-27 2016-11-16 百深公司 凝血蛋白缀合物
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP2470670A4 (en) 2009-08-24 2013-07-10 Amunix Operating Inc COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
SG187171A1 (en) 2010-07-30 2013-02-28 Baxter Int Nucleophilic catalysts for oxime linkage
EP2635297B1 (en) 2010-11-05 2019-02-27 Baxalta GmbH A new variant of antihemophilic factor viii having increased specific activity
JP6088435B2 (ja) 2010-12-15 2017-03-01 バクスアルタ ゲーエムベーハー 導電率グラディエントを用いる溶出液収集
RU2013131911A (ru) * 2010-12-16 2015-01-27 Ново Нордиск А/С Водный раствор фактора viii
JP6138052B2 (ja) 2010-12-22 2017-05-31 バクスアルタ ゲーエムベーハー 水溶性脂肪酸誘導体をタンパク質に抱合させるための材料および方法
HUE043537T2 (hu) 2012-02-15 2019-08-28 Bioverativ Therapeutics Inc Rekombináns VIII faktor fehérjék
HUE060629T2 (hu) 2012-02-15 2023-03-28 Bioverativ Therapeutics Inc VIII. faktor készítmények és eljárások elõállításukra és alkalmazásukra
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
US9212357B2 (en) 2012-12-03 2015-12-15 Omrix Biopharmaceuticals Ltd. Thrombin solution and methods of use thereof
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
HUE047933T2 (hu) * 2013-03-15 2020-05-28 Bioverativ Therapeutics Inc Faktor VIII polipeptid készítmények
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
PT3041513T (pt) 2013-09-08 2020-09-07 Kodiak Sciences Inc Conjugados de polímeros zwiteriónicos com fator viii
NZ722391A (en) 2014-02-04 2022-12-23 Biogen Ma Inc Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CA2943034C (en) * 2014-03-24 2022-06-14 Biogen Ma Inc. Lyophilized factor ix formulations
EP3125925A4 (en) * 2014-04-01 2017-12-06 Advantech Bioscience Farmacêutica Ltda. Stabilization of factor viii without calcium as an excipient
US9907835B2 (en) 2014-04-01 2018-03-06 Advanced Bioscience Farmacêutica LTDA Stable Factor VIII formulations with low sugar-glycine
WO2016012595A1 (en) * 2014-07-25 2016-01-28 Csl Behring Gmbh Improved factor viii preparations suitable for therapeutic use and processes to obtain these
ES2788870T3 (es) 2014-08-04 2020-10-23 Csl Ltd Formulación de factor VIII
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
US10568948B2 (en) 2015-05-13 2020-02-25 Agenus Inc. Vaccines for treatment and prevention of cancer
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
JP6909203B2 (ja) 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
US20190209475A1 (en) * 2015-11-05 2019-07-11 Novo Nordisk A/S FVIII Formulation
EP3167877A1 (en) 2015-11-12 2017-05-17 Bayer Pharma Aktiengesellschaft Method for the production of freeze-dried pellets comprising factor viii
TW201731869A (zh) 2015-12-03 2017-09-16 百克莎塔股份有限公司 具有延長之半衰期及降低之配位體結合性質的因子ｖｉｉｉ
CN111295094A (zh) 2017-10-09 2020-06-16 泰尔茂比司特生物技术有限公司 冻干容器及使用冻干容器的方法
AU2019261451A1 (en) 2018-04-26 2020-12-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CA3224729A1 (en) 2019-03-14 2020-09-17 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
JP2022538357A (ja) 2019-07-04 2022-09-01 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ＶＩＩＩ凝固因子のｉｎ ｖｉｔｒｏでの安定性を向上させるための切断型フォン・ヴィレブランド因子（ＶＷＦ）
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
MX2022014410A (es) * 2020-05-22 2022-12-06 R Pharm Overseas Inc INHIBIDOR DE IL-1ß DERIVADO DE IL1-R1 Y USO DEL MISMO.
WO2022099223A2 (en) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
CA3220564A1 (en) * 2021-06-23 2022-12-29 Bioverativ Therapeutics Inc. Formulations of factor viii chimeric proteins and uses thereof
TW202334244A (zh) * 2021-10-15 2023-09-01 美商百歐維拉提夫治療公司 因子ｖｉｉｉ嵌合蛋白的配製品及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4165370A (en) * 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3176491D1 (en) * 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
DE69010518T2 (de) * 1989-01-30 1994-11-03 Corint Ltd Wässerige Desmopressin-CMC enthaltende Arzneizubereitung.
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer

Also Published As

Publication number Publication date
DE69329795T2 (de) 2001-07-05
FI942573A (fi) 1994-06-01
EP1652534A3 (en) 2007-05-02
DE69333974T2 (de) 2006-08-03
ATE316981T1 (de) 2006-02-15
EP1652534A2 (en) 2006-05-03
SK65994A3 (en) 1995-03-08
PT627924E (pt) 2001-05-31
JPH07501560A (ja) 1995-02-16
FI111443B (fi) 2003-07-31
EP0627924B1 (en) 2000-12-27
NO942033D0 (no) 1994-06-01
FI942573A0 (fi) 1994-06-01
CZ290342B6 (cs) 2002-07-17
JP3905921B2 (ja) 2007-04-18
ES2154650T3 (es) 2001-04-16
CA2124690C (en) 2007-09-11
US5919766A (en) 1999-07-06
AU5288393A (en) 1994-04-26
DE69329795D1 (de) 2001-02-01
KR100303872B1 (ko) 2001-11-22
NO942033L (no) 1994-06-01
EP0627924A1 (en) 1994-12-14
DK0627924T3 (da) 2001-04-30
WO1994007510A1 (en) 1994-04-14
HU220194B (hu) 2001-11-28
EP1016673B1 (en) 2006-02-01
CZ132894A3 (en) 1994-11-16
HU9401382D0 (en) 1994-08-29
HU211670A9 (en) 1995-12-28
ATE198277T1 (de) 2001-01-15
MX9306133A (es) 1994-04-29
AU677797B2 (en) 1997-05-08
SK282483B6 (sk) 2002-02-05
EP1016673A1 (en) 2000-07-05
US5733873A (en) 1998-03-31
DE69333974D1 (de) 2006-04-13
CA2124690A1 (en) 1994-04-14
NZ256921A (en) 1996-05-28
GR3035472T3 (en) 2001-05-31

Similar Documents

Publication Publication Date Title
HU9401382D0 (en) Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
EP1225168A3 (en) Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
MY113022A (en) Novel pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present
HK1014026A1 (en) Enzyme stabilizing composition and the use thereof in stabilized enzyme containing built detergent compositions
TW224970B (hu)
DE59308628D1 (de) Verfahren zur Herstellung von Faktor VIII
ES2026314A6 (es) Procedimiento para obtener una composicion profilactica antimicrobiana oftalmica neonatal.
CA2015919A1 (fr) Composition nettoyante
ZA878249B (en) Method and therapeutic compositions for the treatment of bleeding disorders
IL101180A0 (en) Indane derivatives,their preparation and their use as fragrance materials
IL103856A0 (en) Aminoalkyl-substituted 5,6-dihydro-dibenz(b,e)azepin-6,11-dione-11-oximes,their preparation and pharmaceutical compositions containing them
EP0928792A3 (en) Bicyclic(3.1.0)hexanes and related compounds
ZA937266B (en) Composition comprising coagulation factor VIII formulation process for its preparation and use of a surfactant as stabilizer
EG20734A (en) Pesticides

Legal Events

Date Code Title Description
DGB9 Succession in title of applicant

Owner name: GENETICS INSTITUTE INC.,, US

HPC4 Succession in title of patentee

Owner name: GENETICS INSTITUTE, LLC, US